Compare 8x8 Inc (EGHT) vs Novo Nordisk A/S (NVO) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
8x8 Inc vs Novo Nordisk A/S — how do they compare? 8x8 Inc trades at $2 (market cap $309.09M), while Novo Nordisk A/S trades at $46.38 (market cap $207.85B). The key difference: Novo Nordisk A/S is far larger — about 672.5× 8x8 Inc's market cap, and Novo Nordisk A/S pays a 3.81% dividend while 8x8 Inc pays none. Which is the better fit depends on your goals.
| EGHT | NVO | |
|---|---|---|
Market Cap | $309.09M | $207.85B |
Sector | Technology | Health |
52-Week High | $2.76 | $63.98 |
52-Week Low | $1.59 | $35.29 |
Enterprise Value | $576.02M | $222.55B |
Dividend Yield | — | 3.81% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
EGHT trades at $2.01, down 10.27% today, with a bullish technical signal from moving averages. The company shows improving fundamentals with three consecutive quarterly EPS beats and projected profitability in 2026. Recent news highlights AI platform expansion and partner program enhancements driving growth.
The outlook appears constructive with analyst consensus target of $3.13 representing 56% upside potential. Key risks include high debt levels and negative retained earnings, while catalysts include continued AI adoption and revenue growth acceleration toward profitability.
Novo Nordisk (NVO) trades at $46.465, down 2.65% today, with a neutral technical signal. The stock shows strong fundamentals, including a P/E of 11.62, net income margin of 35.35%, and consistent earnings beats in recent quarters. Recent news highlights competitive pressures from Eli Lilly and mixed investor reactions to Q2 2026 results, despite an upwardly revised full-year outlook.
Outlook remains positive due to robust GLP-1 drug demand and profitability, but risks include pricing pressure and competition. Analysts are predominantly bullish (57.9% buy ratings), supporting a favorable long-term view despite near-term volatility.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About 8x8 Inc
8x8 is a provider of integrated cloud communications and contact center solutions. Its platform combines voice, video, chat, and contact center functionality into a single application to help businesses collaborate.
Read more on EGHT →About Novo Nordisk A/S
With almost 50% market share by volume of the global insulin market, Novo Nordisk is the leading provider of diabetes-care products in the world. Based in Denmark, the company manufactures and markets a variety of human and modern insulins, injectable diabetes treatments, and oral antidiabetic agents. Novo also has a biopharmaceutical segment (constituting roughly 15% of revenue) that specializes in protein therapies for hemophilia and other disorders.
Read more on NVO →
